AI－200是Autolmmune公司最近研制的一种用于治疗风湿病的新药。11期临床试验表明，“口服耐受”方法治疗自身免疫性疾病是有效的。Trentham等报道，28例严重风湿性关节炎患者，口服AI－200（溶解11型鸡胶原蛋白）3个月后，结果有4例患者完全缓解（l％），而用安慰剂治疗的对照 AI-200 is a new drug recently developed by Autolmmune for the treatment of rheumatism. Phase 11 clinical trials have shown that “oral tolerance” is an effective treatment of autoimmune diseases. Trentham et al. Reported that in 28 patients with severe rheumatoid arthritis, 4 patients achieved complete remission (1%) after 3 months of oral administration of AI-200 (collagen type 11 collagen), whereas placebo-treated controls